<?xml version='1.0' encoding='utf-8'?>
<document id="17713972"><sentence text="Clinical pharmacokinetics of darunavir."><entity charOffset="29-38" id="DDI-PubMed.17713972.s1.e0" text="darunavir" /></sentence><sentence text="Darunavir (TMC114) is a newly developed HIV-1 protease inhibitor with potent antiviral activity against both wild-type and multidrug resistant HIV-1 strains"><entity charOffset="0-9" id="DDI-PubMed.17713972.s2.e0" text="Darunavir" /><entity charOffset="11-17" id="DDI-PubMed.17713972.s2.e1" text="TMC114" /><pair ddi="false" e1="DDI-PubMed.17713972.s2.e0" e2="DDI-PubMed.17713972.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17713972.s2.e0" e2="DDI-PubMed.17713972.s2.e1" /></sentence><sentence text=" The drug is currently approved by the US FDA for antiretroviral treatment-experienced patients with limited therapeutic options" /><sentence text=" The approved dosage of darunavir is 600 mg in combination with ritonavir 100mg twice daily"><entity charOffset="24-33" id="DDI-PubMed.17713972.s4.e0" text="darunavir" /><entity charOffset="64-73" id="DDI-PubMed.17713972.s4.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.17713972.s4.e0" e2="DDI-PubMed.17713972.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17713972.s4.e0" e2="DDI-PubMed.17713972.s4.e1" /></sentence><sentence text=" Darunavir is rapidly absorbed after oral administration, reaching peak plasma concentrations after 2"><entity charOffset="1-10" id="DDI-PubMed.17713972.s5.e0" text="Darunavir" /></sentence><sentence text="5-4 hours" /><sentence text=" Absorption is followed by a fast distribution/elimination phase and a subsequent slower elimination phase with a terminal elimination half-life of 15 hours in the presence of low-dose ritonavir"><entity charOffset="185-194" id="DDI-PubMed.17713972.s7.e0" text="ritonavir" /></sentence><sentence text=" Darunavir is approximately 95% plasma protein bound, mainly to alpha(1)-acid glycoprotein"><entity charOffset="1-10" id="DDI-PubMed.17713972.s8.e0" text="Darunavir" /></sentence><sentence text=" Systemic exposure is increased by 30% when darunavir is taken with a meal"><entity charOffset="44-53" id="DDI-PubMed.17713972.s9.e0" text="darunavir" /></sentence><sentence text=" Darunavir is extensively and almost exclusively metabolised by cytochrome P450 (CYP) 3A4"><entity charOffset="1-10" id="DDI-PubMed.17713972.s10.e0" text="Darunavir" /></sentence><sentence text=" Coadministration with small doses of the strong CYP3A4 inhibitor ritonavir results in an increase in darunavir bioavailability from 37% to 82%"><entity charOffset="66-75" id="DDI-PubMed.17713972.s11.e0" text="ritonavir" /><entity charOffset="102-111" id="DDI-PubMed.17713972.s11.e1" text="darunavir" /><pair ddi="false" e1="DDI-PubMed.17713972.s11.e0" e2="DDI-PubMed.17713972.s11.e0" /><pair ddi="false" e1="DDI-PubMed.17713972.s11.e0" e2="DDI-PubMed.17713972.s11.e1" /></sentence><sentence text=" Darunavir and its metabolites are mainly excreted in faeces (79"><entity charOffset="1-10" id="DDI-PubMed.17713972.s12.e0" text="Darunavir" /></sentence><sentence text="5%) and, to a lesser extent, in urine (13" /><sentence text="9%)" /><sentence text=" With regard to the necessary coadministration with low-dose ritonavir as a potent CYP3A4 inhibitor, coadministration of other substrates of CYP3A4 with darunavir/ritonavir requires caution or is even contraindicated"><entity charOffset="61-70" id="DDI-PubMed.17713972.s15.e0" text="ritonavir" /><entity charOffset="153-162" id="DDI-PubMed.17713972.s15.e1" text="darunavir" /><entity charOffset="163-172" id="DDI-PubMed.17713972.s15.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.17713972.s15.e0" e2="DDI-PubMed.17713972.s15.e0" /><pair ddi="false" e1="DDI-PubMed.17713972.s15.e0" e2="DDI-PubMed.17713972.s15.e1" /><pair ddi="false" e1="DDI-PubMed.17713972.s15.e0" e2="DDI-PubMed.17713972.s15.e2" /><pair ddi="false" e1="DDI-PubMed.17713972.s15.e1" e2="DDI-PubMed.17713972.s15.e1" /><pair ddi="false" e1="DDI-PubMed.17713972.s15.e1" e2="DDI-PubMed.17713972.s15.e2" /></sentence><sentence text=" Guidance is derived from drug-drug interaction trials and experience from comparable ritonavir-boosted protease inhibitor regimens"><entity charOffset="86-95" id="DDI-PubMed.17713972.s16.e0" text="ritonavir" /></sentence><sentence text="" /></document>